This study revealed the critical role of CD36-mediated FA uptake in HER2 + therapy-resistant BC and provided evidence of persistent enrichment of CD36 in HER2 + EMT-like CSCs that are refractory to anti-HER2 therapy due to Wnt pathway activation. The gene discussed is ERBB2; the disease is breast cancer.